

**Curriculum Vitae**

**Payam Peymani, Pharm.D., PhD**  
**Assistant Professor, Visiting Professor**  
**Last Update: September , 2019**

**Personal Data:**

Name: Payam  
Surname: Peymani  
Sex: Male  
Nationality: Iranian  
Marital Status: Married  
Date and Place of Birth: 26 May, 1985, Shiraz, Iran  
E-mail: peymani.payam@gmail.com, Cell Phone: +41-76 619 74 12

**Contact Address:**

Department of Clinical Pharmacology & Toxicology, University Hospital Zürich, RAE E, Rämistrasse 100, 8091, Zurich, Switzerland.  
Payam.peymani@usz.ch

**Position:**

**Visiting Professor**, Department of Clinical Pharmacology & Toxicology, University Hospital Zürich, Zurich, Switzerland.  
**-Director of** Permanent Secretariat of Euro-Asian Pharmacoepidemiology Congress (**EAPEC**)  
**-Assistant Professor and Director** of Pharmacoepidemiology and Pharmacoeconomics Group, Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

**PUBLICATION RECORD:**

<b>Total Publications:</b> 40 Scopus/ 53 Google Scholar	<b>h-Index</b>	<b>Number of Citations</b>	<b>Source of Citation Data</b>
	11	369	Scopus
	12	646	Google Scholar

**Find me at authors' profiles systems:**

-ISI Researcher ID: S-7386-2017  
-Scopus author ID: 35269952500  
-Google (scholar) citation service:  
URL: <https://scholar.google.com/citations?user=Q1fXGjQAAAAJ&hl=en&oi=ao>  
-ORCID (Open Researcher & Contributor ID): [orcid.org/0000-0002-7223-8590](https://orcid.org/0000-0002-7223-8590)

**Find Me at Academic Social Networks:**

-Research Gate: [https://www.researchgate.net/profile/Payam\\_Peymani](https://www.researchgate.net/profile/Payam_Peymani)  
-LinkedIn: <https://www.linkedin.com/in/peymani-payam-93b34782>

## **ACADEMIC QUALIFICATIONS:**

1. July 2019: **Visiting Professor**, Department of Clinical Pharmacology & Toxicology, University Hospital Zürich, Zurich, Switzerland.
2. June 2018: **Postdoctoral Short Course**, Pharmacoepidemiology Group, Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
3. March 2016–December 2016: **Postdoctoral course/Senior Research Fellow**, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
4. 2012-2016: **PhD in Clinical Pharmacology (Pharmacoepidemiology)**, Shiraz University of Medical Sciences, Shiraz, Iran.
5. 2003-2010: **Pharm.D.** (Doctor of Pharmacy), Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

## **Publication (PubMed):**

<https://www.ncbi.nlm.nih.gov/pubmed/?term=payam+peymani>

## **Publication (Scops):**

<https://www.scopus.com/authid/detail.uri?authorId=35269952500>

## **Scientific Interests and Working Area:**

Drug Safety, Pharmacovigilance, Pharmacoepidemiology, Clinical Trial (Clinical Trials Design and Management), Population Based Study and Clinical Pharmacology Study

## **Worked Experiences (Summary of Experience):**

Over six years of experience in Clinical Research and pharmacoepidemiology field as Clinical Research Manager, senior clinical Research Associated.

**Teaching experiences (Instructing background):** more than 5 years' experience as lecturer of related pharmacy and pharmaceutical courses and classes.

**Peer- Review and Editorial Activity:** Reviewer and Associated Editor of international journals.

**Skills:** *Statistics programs, bibliography software, Dynamic Presentation Software Prezi, PowerPoint, Clinical Trial and Research, some Laboratory techniques.*

**Mentoring and Co-Supervision:** Four undergraduate and postgraduate students' thesis

## **Memberships:**

1. June 2012-Present: The International Society for Pharmacoepidemiology (ISPE)
2. December 2010-Present: Iranian Pharmaceutical Association (IPhA).
3. March 2010-Present: Iranian Medical Council (IMC).

## **Some National and International Grants:**

1. Post marketing surveillance of liver injury caused by drugs: prospective analysis of drug-induced liver injury cases in a major Swiss university hospital and comparison with retrospective cases extracted from the Swiss Pharmacovigilance database in the years, **University of Zurich and University hospital Zurich, 2014-2018.**
2. Predictors of switching to Insulin in oral anti diabetic (oral hypoglycemic) agent users (Population Based Study), **Funded by Erasmus MC (Rotterdam, the Netherlands), 2018-2020**

3. Gender based non-communicable diseases in Iranian women, **Shiraz University of medical Sciences (SUMS) Grant, 2018-2020**

4-Pharmacovigilance of MS Medication: 2017-2019, **SUMS Grant**

5- Essential Hypoglycemic (Anti Diabetes) and cardiovascular medicine list compilation in Iran health system (**National Grant from FDA of Iran**)

6-Measuring medicine prices, availability, affordability and price components for Hypoglycemic (Anti Diabetes) and cardiovascular medicine (**National Grant from FDA of Iran**).

7. and Asthma: How does autophagy regulate airway remodeling via affecting airway mesenchymal cells). (**National Grant from NIMAD**) (2018-2019)

8- Mevalonate Cascade Inhibition Sensitizes Human Glioblastoma Cells to Temozolomide via Modulation of Autophagy (**National Grant from NIMAD**) (2018-2019)

9-Evaluation of International Indicators of patients care in Shiraz Pharmacy Store, 2017-2018, Completed, Funded by **SUMS**

10. Evaluation of accessibility and variety of medications available to Shiraz community (households) in Shiraz-1395: A Population-Based Study. (2016-2018), Completed, **Funded by SUMS**

11- Effect of octreotide in control of nonvariceal upper GI bleeding: randomized control trial: randomized double blind controlled trial. Completed (2014-2016), Completed, **Funded by SUMS**

12. The therapeutic effect of Midodrine in patients with refractory gastro esophageal reflux disease: a randomized double-blind clinical trial. Completed, (2014-2016), **Funded by SUMS**

13-Chloroquine Therapy for Non-Responsive HCV Patients Genotype. **Completed (2012-2014), Funded by Manitoba University, Canada and SUMS**

14. Autophagy, and Endoplasmic Reticulum Stress in Autoimmune Hepatitis: A Clinical Pilot Study. **Completed (2013-2015), Funded by Manitoba University, Canada and SUMS.**

Payam Peymani is currently is currently visiting professor at Department of Clinical Pharmacology & Toxicology, University Hospital Zürich, Zurich, Switzerland. In addition, he is an Assistant Professor and Director of Pharmacoepidemiology and Pharmacoeconomics Group, Health Policy Research Center of Shiraz University of Medical Sciences. He is the author of more than 50 peer review papers, and participated and gave presentation in more than 34 international Congress and symposia and has been a reviewers of various international scientific journals. He is an Editorial Manager and Associated Editor of the Social Pharmacy Journal. Dr. Peymani has a more than 6 years' experience of designing and conducting clinical trials: as Clinical Research Manager and senior clinical Research Associate, Statistical and Epidemiological consultant of Clinical Trials projects of University of Medical Sciences in Iran. He is expert in Design and Conduct and Analysis-documentation of Clinical trials, Responsible for monitoring the progress of clinical studies and assessing standard operating procedures (SOPs) and drug safety projects. Dr Peymani obtained his PhD of Clinical Pharmacology (Pharmacoepidemiology) from Health Policy Research Center, Shiraz University of Medical Sciences in 2013 and 2016 respectively. He received his Pharmacy Doctorate (Pharm.D) degree in Pharmaceutical Sciences from Faculty of Pharmacy, Shiraz University of Medical Sciences in 2010. Currently, His is involved in Pharmacoepidemiology, Pharmacovigilance and Drug safety study and his main research interest is in the design and conduct Clinical Trial and Pharmacoepidemiology and drug safety Evaluation.